NOT-FD-21-008: Notice to correct email address for submission of Letter of Intent - RFA-FD-21-016 -Development of Advanced Analytical Methods for the Characterization of Iron Carbohydrate Complex

Notice to correct email address for submission of Letter of Intent - RFA-FD-21-016 -Development of Advanced Analytical Methods for the Characterization of Iron Carbohydrate Complex - Ferric Derisomaltose (U01)

Notice Number:

NOT-FD-21-008

Key Dates

Release Date:

February 10, 2021

Related Announcements

RFA-FD-21-016 - Development of Advanced Analytical Methods for the Characterization of Iron Carbohydrate Complex - Ferric Derisomaltose (U01) Clinical Trials Not Allowed

Issued by

U.S. Food and Drug Administration (FDA)

Purpose

This notice is to make a correction to the email address listed for the submission of the Letter of Intent for RFA-FD-21-016 -Development of Advanced Analytical Methods for the Characterization of Iron Carbohydrate Complex - Ferric Derisomaltose (U01) Clinical Trials Not Allowed.

The letter of intent should be sent to:

Shashi Malhotra
Telephone: 240-402-7592
Email:shashi.malhotra@fda.hhs.gov

Inquiries

Please direct all inquiries to:

Shashi Malhotra
Grants Management Specialist
Office if Acquisitions and Grants Services
Tel: 240-402-7592
Email: Shashi.Malhotra@fda.hhs.gov